HC Wainwright Raises Kura Oncology (NASDAQ:KURA) Price Target to $40.00

Kura Oncology (NASDAQ:KURA) had its price objective hoisted by stock analysts at HC Wainwright from $37.00 to $40.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 362.43% from the stock’s current price.

A number of other brokerages have also recently weighed in on KURA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Scotiabank dropped their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Price Performance

KURA stock opened at $8.65 on Thursday. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $672.62 million, a price-to-earnings ratio of -3.67 and a beta of 0.78. The business has a fifty day moving average of $8.79 and a two-hundred day moving average of $15.11.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period last year, the company earned ($0.50) EPS. As a group, research analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock valued at $100,739 in the last quarter. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new position in Kura Oncology in the second quarter valued at approximately $541,000. AQR Capital Management LLC lifted its position in shares of Kura Oncology by 251.5% during the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after buying an additional 58,422 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the last quarter. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter worth $25,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after acquiring an additional 5,788 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.